BACKGROUND: Lyme disease patients with erythema migrans are said to have post-treatment Lyme disease symptoms (PTLDS) if there is persistence of subjective symptoms for at least 6 months following antibiotic treatment and resolution of the skin lesion. The purpose of this study was to characterize PTLDS in patients with culture-confirmed early Lyme disease followed for >10 years. METHODS: Adult patients with erythema migrans with a positive skin or blood culture for Borrelia burgdorferi were enrolled in a prospective study beginning in 1991 and followed up at 6 months and annually thereafter to determine the long-term outcome of this infection. The genotype of the infecting strain of B. burgdorferi was evaluated in subjects with PTLDS. RESULTS: One hundred twenty-eight subjects with culture-confirmed early Lyme disease, of whom 55% were male, were followed for a mean ± SD of 14.98 ± 2.71 years (median = 15 years; range = 11-20 years). Fourteen (10.9%) were regarded as having possible PTLDS, but only 6 (4.7%) had PTLDS documented at their last study visit. Nine (64.3%) had only a single symptom. None of the 6 with PTLDS at their last visit was considered to be functionally impaired by the symptom(s). PTLDS was not associated with a particular genotype of B. burgdorferi. CONCLUSIONS: PTLDS may persist for >10 years in some patients with culture-confirmed early Lyme disease. Such long-standing symptoms were not associated with functional impairment or a particular strain of B. burgdorferi.
BACKGROUND:Lyme diseasepatients with erythema migrans are said to have post-treatment Lyme disease symptoms (PTLDS) if there is persistence of subjective symptoms for at least 6 months following antibiotic treatment and resolution of the skin lesion. The purpose of this study was to characterize PTLDS in patients with culture-confirmed early Lyme disease followed for >10 years. METHODS: Adult patients with erythema migrans with a positive skin or blood culture for Borrelia burgdorferi were enrolled in a prospective study beginning in 1991 and followed up at 6 months and annually thereafter to determine the long-term outcome of this infection. The genotype of the infecting strain of B. burgdorferi was evaluated in subjects with PTLDS. RESULTS: One hundred twenty-eight subjects with culture-confirmed early Lyme disease, of whom 55% were male, were followed for a mean ± SD of 14.98 ± 2.71 years (median = 15 years; range = 11-20 years). Fourteen (10.9%) were regarded as having possible PTLDS, but only 6 (4.7%) had PTLDS documented at their last study visit. Nine (64.3%) had only a single symptom. None of the 6 with PTLDS at their last visit was considered to be functionally impaired by the symptom(s). PTLDS was not associated with a particular genotype of B. burgdorferi. CONCLUSIONS:PTLDS may persist for >10 years in some patients with culture-confirmed early Lyme disease. Such long-standing symptoms were not associated with functional impairment or a particular strain of B. burgdorferi.
Authors: Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: G P Wormser; D Liveris; J Nowakowski; R B Nadelman; L F Cavaliere; D McKenna; D Holmgren; I Schwartz Journal: J Infect Dis Date: 1999-09 Impact factor: 5.226
Authors: Gary P Wormser; Dustin Brisson; Dionysios Liveris; Klára Hanincová; Sabina Sandigursky; John Nowakowski; Robert B Nadelman; Sara Ludin; Ira Schwartz Journal: J Infect Dis Date: 2008-11-01 Impact factor: 5.226
Authors: B A Fallon; J G Keilp; K M Corbera; E Petkova; C B Britton; E Dwyer; I Slavov; J Cheng; J Dobkin; D R Nelson; H A Sackeim Journal: Neurology Date: 2007-10-10 Impact factor: 9.910
Authors: John Nowakowski; Robert B Nadelman; Rebecca Sell; Donna McKenna; L Frank Cavaliere; Diane Holmgren; Adriana Gaidici; Gary P Wormser Journal: Am J Med Date: 2003-08-01 Impact factor: 4.965
Authors: Mark S Klempner; Phillip J Baker; Eugene D Shapiro; Adriana Marques; Raymond J Dattwyler; John J Halperin; Gary P Wormser Journal: Am J Med Date: 2013-06-10 Impact factor: 4.965
Authors: L B Krupp; L G Hyman; R Grimson; P K Coyle; P Melville; S Ahnn; R Dattwyler; B Chandler Journal: Neurology Date: 2003-06-24 Impact factor: 9.910
Authors: Allen C Steere; Franc Strle; Gary P Wormser; Linden T Hu; John A Branda; Joppe W R Hovius; Xin Li; Paul S Mead Journal: Nat Rev Dis Primers Date: 2016-12-15 Impact factor: 52.329
Authors: Gary P Wormser; Donna McKenna; Carol L Karmen; Keith D Shaffer; Jesse H Silverman; John Nowakowski; Carol Scavarda; Eugene D Shapiro; Paul Visintainer Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: Gary P Wormser; Praveen Sudhindra; Eliana Lopez; Lisa Patel; Sara Rezai; Aaron D Brumbaugh; Donna McKenna; Carol Scavarda; Eugene D Shapiro; Carol L Karmen; Paul Visintainer Journal: Diagn Microbiol Infect Dis Date: 2016-07-27 Impact factor: 2.803
Authors: Jack Reifert; Kathy Kamath; Joel Bozekowski; Ewa Lis; Elizabeth J Horn; Dane Granger; Elitza S Theel; John Shon; Jaymie R Sawyer; Patrick S Daugherty Journal: J Clin Microbiol Date: 2021-01-21 Impact factor: 5.948